AbbVie, Bristol Myers Squibb, Gilead, Merck and other drugmakers are expected on Friday afternoon to announce agreements ...
President Donald Trump is expected to announce on Friday new agreements aimed at lowering prescription drug prices, the ...
Iceland-based biosimilars developer Alvotech and a US affiliate of Israel’s Teva Pharmaceutical Industries, today announced ...
It's full steam ahead for a new Regeneron facility in Saratoga Springs. The company has learned that Saratoga County's ...
“For many years, the standard of care for ASHL was based on the RATHL trial, where newly diagnosed patients were given two cycles of ABVD [doxorubicin, bleomycin, vinblastine, and dacarbazine] and ...
With T-cell engagers already established as late-line therapies for certain blood cancers, Regeneron has released early data ...
According to the settlement agreement, the proposed biosimilar to Eylea® (aflibercept) can be marketed in the U.S., if ...
According to the settlement agreement, the proposed biosimilar to Eylea (aflibercept) can be marketed in the U.S., if approved by the FDA, in the fourth quarter of 2026, or earlier under certain circu ...
The White House is set to announce drug pricing deals with pharmaceutical heavyweights Novartis AG and Roche Holding AG as ...
Following FDA rejections, Regeneron and Scholar Rock are turning to other facilities to clear regulatory logjams created by quality problems at an ex-Catalent facility in Indiana. Novo Nordisk, ...
LIB Therapeutics has scored an FDA approval for its cholesterol-lowering, third-generation PCSK9 inhibitor, lerodalcibep-liga ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback